# Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients

> **NCT02432833** · PHASE4 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 428 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** ENVARSUS®
- **DRUG:** PROGRAF®
- **DRUG:** ADVAGRAF®

## Key facts

- **NCT ID:** NCT02432833
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2017-01-24
- **Final completion:** 2017-01-24
- **Target enrollment:** 428 (ACTUAL)
- **Last updated:** 2018-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02432833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02432833, "Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02432833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*